Tofacitinib: A novel oral janus kinase inhibitor for rheumatoid arthritis

Formulary

Volumn 47, Issue 10, 2012, Pages 350-353

  O'Dell, Kate M ^a,b   Rummel, Ashley E ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b St Joseph's Medical Center Stockton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; TOFACITINIB;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FUNCTIONAL STATUS; HUMAN; INFECTION; INTRACELLULAR SIGNALING; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEOPLASM; PLASMA PROTEIN BINDING; REMISSION; RHEUMATOID ARTHRITIS; SELF REPORT; STEADY STATE; TREATMENT RESPONSE; URINARY EXCRETION;

EID: 84869830253     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Article

References (0)